The decision to administer antifungal prophylaxis depends on the risk [stratification](href) of the patient. High-risk groups include:
- Patients with prolonged neutropenia: Typically those undergoing [chemotherapy](href) for hematologic malignancies. - Stem cell and organ transplant recipients: They are often given prophylaxis to prevent invasive fungal infections during the post-transplant period. - Patients with advanced HIV/AIDS: They are at high risk for opportunistic infections like [Pneumocystis jirovecii pneumonia](href) (PCP) and cryptococcosis.
